Shares of Regeneron Pharmaceuticals, Inc. REGN have dropped 15.5% in the year so far compared with the industry’s decline of ...

Current price $770.33 52-week high $1,211.20 ...

Positive clinical trial results for Merck & Co's experimental antiviral COVID-19 pill reverberated through the health care sector on Friday, sending the drugmaker's stock price soaring while ...

Stocks generally enjoyed one of the best months of the year. Here's what else you should know about the markets into year-end.

If an investor was to purchase shares of REGN stock at the current price level of $756.89/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock ...

REGN dropped to an RSI of about 10 ... the outcome of the DOJ case and the amount of the potential fine. The stock price may also have limited upside until a decision is made in the courts.

According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $1,099.55. REGN stock opened at $756.81 on Wednesday.

Biotech companies are making monumental strides in cancer treatment, leveraging cutting-edge technologies to redefine the ...